Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
BMJ Case Reports
|
June 21, 2011
A deadly cargo
Simon William Dubrey, Simon Peake
AIDS (London, England)
|
November 6, 2019
Vedolizumab use and the associations between α4β7 expression and HIV reservoir in the gut during treated primary HIV infection
John P Thornhill, Kate D Lynch, Jessica K Skelton, et al.
British Journal of Hospital Medicine (London, England : 2005)
|
November 2, 2021
Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis
Ayesha Akbar, Ian Arnott, Nicholas A Kennedy, et al.
Mucosal Immunology
|
June 27, 2019
CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype
John P Thornhill, Matthew Pace, Genevieve E Martin, et al.
Frontline Gastroenterology
|
September 2, 2022
Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
Charles Miller, Hanson Kwok, Paul Harrow, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
BMJ Case Reports
|
June 21, 2011
A deadly cargo
Simon William Dubrey, Simon Peake
AIDS (London, England)
|
November 6, 2019
Vedolizumab use and the associations between α4β7 expression and HIV reservoir in the gut during treated primary HIV infection
John P Thornhill, Kate D Lynch, Jessica K Skelton, et al.
British Journal of Hospital Medicine (London, England : 2005)
|
November 2, 2021
Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis
Ayesha Akbar, Ian Arnott, Nicholas A Kennedy, et al.
Mucosal Immunology
|
June 27, 2019
CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype
John P Thornhill, Matthew Pace, Genevieve E Martin, et al.
Frontline Gastroenterology
|
September 2, 2022
Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
Charles Miller, Hanson Kwok, Paul Harrow, et al.
Page
of 1